# Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

> **NCT04846959** · — · RECRUITING · sponsor: **AbbVie** · enrollment: 818 (estimated)

## Conditions studied

- Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Comparator

## Key facts

- **NCT ID:** NCT04846959
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-30
- **Primary completion:** 2032-06
- **Final completion:** 2032-06
- **Target enrollment:** 818 (ESTIMATED)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04846959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04846959, "Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04846959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*